Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02422615
Registration number
NCT02422615
Ethics application status
Date submitted
1/04/2015
Date registered
21/04/2015
Date last updated
30/11/2023
Titles & IDs
Public title
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
Query!
Scientific title
A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment
Query!
Secondary ID [1]
0
0
2015-000617-43
Query!
Secondary ID [2]
0
0
CLEE011F2301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MONALEESA-3
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ribociclib
Treatment: Drugs - Fulvestrant
Treatment: Drugs - Placebo
Experimental: Ribociclib + fulvestrant - Ribociclib was administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1. For participants who did not tolerate the protocol-specified dosing schedule, dose adjustments were permitted in order to allow the patient to continue the study treatment.
Placebo Comparator: Placebo + fulvestrant - Placebo was administered orally for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1. For participants who did not tolerate the protocol-specified dosing schedule, dose adjustments were permitted in order to allow the patient to continue the study treatment.
Participants were unblinded after the implementation of protocol amendment 4 (29-Jan-20) and were given the option to crossover to treatment with ribociclib and fulvestrant.
Treatment: Drugs: Ribociclib
Ribociclib capsules were administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle.
Treatment: Drugs: Fulvestrant
Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.
Treatment: Drugs: Placebo
Placebo capsules were administered orally for 21 consecutive days within a 28-day cycle.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS) Per Investigator Assessment
Query!
Assessment method [1]
0
0
PFS was defined as the period starting from the date of randomization to the date of the first documented progression or death caused by any reason. In cases where patients did not experience an event, the PFS was censored at the date of the last adequate tumor assessment. Clinical deterioration without objective radiological evidence was not considered as documented disease progression.
PFS was assessed via local radiology assessment according to RECIST 1.1. The Kaplan-Meier method was used to estimate PFS, and the median PFS, along with 95% confidence intervals, was reported for each treatment group.
The distribution of PFS between the two arms was compared using a stratified log-rank test at a one-sided 2.5% level of significance. The PFS hazard ratio with two-sided 95% confidence interval was derived from the stratified Cox proportional hazards model.
Query!
Timepoint [1]
0
0
From randomization to first documented progression or death, assessed up to approximately 26 months
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the time from the date of randomization to the date of death from any cause. In cases where the patient's death was not recorded, the OS value was censored at the date of the last known patient's survival status. As per protocol, the final OS analysis was conducted after approximately 351 deaths were documented.
OS was estimated using the Kaplan-Meier method. The median OS, along with 95% confidence intervals (CIs), was reported for each treatment group.
The distribution of OS between the two treatment arms was compared using a log-rank test at one-sided cumulative 2.5% level of significance. A stratified Cox regression was used to estimate the OS hazard ratio and the associated 95% CI.
Query!
Timepoint [1]
0
0
From randomization to death, assessed up to approximately 46 months
Query!
Secondary outcome [2]
0
0
Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC)
Query!
Assessment method [2]
0
0
PFS was defined as the period starting from the date of randomization to the date of the first documented progression or death caused by any reason. In cases where patients did not experience an event, the PFS was censored at the date of the last adequate tumor assessment. Clinical deterioration without objective radiological evidence was not considered as documented disease progression.
PFS was assessed via BIRC assessment according to RECIST 1.1. The Kaplan-Meier method was used to estimate PFS, and the median PFS, along with 95% confidence intervals, was reported for each treatment group.
Query!
Timepoint [2]
0
0
From randomization to first documented progression or death, assessed up to approximately 26 months
Query!
Secondary outcome [3]
0
0
Overall Response Rate (ORR) Per Investigator Assessment
Query!
Assessment method [3]
0
0
ORR was defined as the percentage of participants with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1 as per investigator assessment.
CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [3]
0
0
Up to approximately 26 months
Query!
Secondary outcome [4]
0
0
Clinical Benefit Rate (CBR) Per Investigator Assessment
Query!
Assessment method [4]
0
0
CBR was defined as the percentage of participants with a best overall response of CR or PR or stable disease (SD) lasting 24 weeks or longer as defined in RECIST 1.1 as per investigator assessment.
CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.
Query!
Timepoint [4]
0
0
Up to approximately 26 months
Query!
Secondary outcome [5]
0
0
Time to Response (TTR) Per Investigator Assessment
Query!
Assessment method [5]
0
0
TTR was defined as the time from randomization to the first documented and confirmed response (CR or PR) as defined by RECIST 1.1 per investigator assessment. The Kaplan-Meier method was used to estimate TTR, and the median TTR, along with 95% confidence intervals, was reported for each treatment group. Participants who did not achieve a confirmed response were censored at the maximum follow-up time for patients who had a PFS event (i.e. either progressed or died due to any cause) or at the date of last adequate tumor assessment otherwise.
CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [5]
0
0
From randomization to first response, assessed up to approximately 26 months
Query!
Secondary outcome [6]
0
0
Duration of Response (DOR) Per Investigator Assessment
Query!
Assessment method [6]
0
0
DOR was defined as the time from the first documented response (CR or PR) to the first documented progression or death due to underlying cancer as defined in RECIST 1.1 per investigator assessment. The Kaplan-Meier method was used to estimate DOR, and the median DOR, along with 95% confidence intervals, was reported for each treatment group. If a participant had not had an event, duration was censored at the date of last adequate tumor assessment.
CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [6]
0
0
From first documented response to progression or death, assessed up to approximately 26 months
Query!
Secondary outcome [7]
0
0
Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) in One Score Category
Query!
Assessment method [7]
0
0
ECOG PS categorized patients based on their ability to perform daily activities and self-care, with scores ranging from 0 to 5. A score of 0 indicated no restrictions in activity, while higher scores indicated increasing limitations. Time to definitive deterioration was defined as the time from the date of randomization to the date of the event, defined as experiencing an increase in ECOG PS by at least one category from the baseline or death. A deterioration was considered definitive if no improvements in the ECOG PS were observed at a subsequent time. The Kaplan-Meier method was used to estimate the distribution, and the median time to definitive deterioration, along with 95% confidence intervals, was reported for each treatment group. Patients receiving any further therapy prior to definitive worsening were censored at their date of last assessment prior to start of therapy. Patients that had not worsened at the data cutoff point were censored at the date of last assessment.
Query!
Timepoint [7]
0
0
Up to approximately 26 months
Query!
Secondary outcome [8]
0
0
Time to Definitive 10% Deterioration in the Global Health Status/Quality of Life (GHS/QoL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)
Query!
Assessment method [8]
0
0
The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, a GHS/QoL scale, and 6 single items. GHS/QoL scale scores range between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.
The time to definitive 10% deterioration is defined as the time from the date of randomization to the date of event, which is defined as at least 10% relative to baseline worsening of the QoL score (without further improvement above the threshold) or death due to any cause. The Kaplan-Meier method was used to estimate the distribution, and the median time to definitive 10% deterioration, along with 95% confidence intervals, was reported for each treatment group. If a patient had not had an event, time to deterioration was censored at the date of the last adequate QoL evaluation.
Query!
Timepoint [8]
0
0
Up to approximately 26 months
Query!
Secondary outcome [9]
0
0
Change From Baseline in the GHS/QoL Scale Score of the EORTC QLQ-C30
Query!
Assessment method [9]
0
0
The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, a GHS/QoL scale, and 6 single items. GHS/QoL scale scores range between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.
The change from baseline in the GHS/QoL score was assessed. A positive change from baseline indicates improvement. For subjects who discontinued treatment without disease progression, post-treatment efficacy visits occurred every 8 weeks during the initial 18 months since start of treatment, followed by visits every 12 weeks until disease progression.
Query!
Timepoint [9]
0
0
Baseline, every 8 weeks after randomization during 18 months, then every 12 weeks up to end of treatment; end of treatment; and every 8 or 12 weeks post-treatment until progression (post-treatment efficacy visits), assessed up to approximately 26 months
Query!
Secondary outcome [10]
0
0
Ribociclib Plasma Concentrations
Query!
Assessment method [10]
0
0
Blood samples were collected to assess the concentration by time point for ribociclib. Participants were classified into the following dose groups at each timepoint: 1) ribociclib 600 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 600 mg immediately prior to the blood collection without a dose change or interruption. 2) ribociclib 400 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 400 mg immediately prior to the blood collection without a dose change or interruption. 3) ribociclib 200 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 200 mg immediately prior to the blood collection without a dose change or interruption.
Query!
Timepoint [10]
0
0
Cycle 1 and Cycle 2 at Day 15 pre-dose and at 2, 4, and 6 hours post-dose. Cycle=28 days
Query!
Secondary outcome [11]
0
0
LEQ803 Plasma Concentrations
Query!
Assessment method [11]
0
0
Blood samples were collected to assess the concentration by time point for LEQ803, a metabolite of ribociclib. Participants were classified into the following dose groups at each timepoint: 1) ribociclib 600 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 600 mg immediately prior to the blood collection without a dose change or interruption. 2) ribociclib 400 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 400 mg immediately prior to the blood collection without a dose change or interruption. 3) ribociclib 200 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 200 mg immediately prior to the blood collection without a dose change or interruption.
Query!
Timepoint [11]
0
0
Cycle 1 and Cycle 2 at Day 15 pre-dose and at 2, 4, and 6 hours post-dose. Cycle = 28 days
Query!
Eligibility
Key inclusion criteria
Key
1. Patients were adults, both male and female, aged = 18 years at the time of providing
informed consent. Female patients were required to be postmenopausal. Informed consent
was obtained prior to any trial-related activities, following local guidelines.
2. Patients had a confirmed diagnosis of estrogen-receptor positive and/or progesterone
receptor positive breast cancer, determined through histological and/or cytological
examination by a local laboratory. Patients also had HER2-negative breast cancer.
3. Patients had either measurable disease as per RECIST 1.1 criteria or at least one
predominantly lytic bone lesion.
4. Patients had advanced breast cancer, which included locoregionally recurrent disease
not amenable to curative therapies (such as surgery or radiotherapy) or metastatic
breast cancer. Patients fell into one of the following categories:
- Newly diagnosed with advanced/metastatic breast cancer and treatment-naïve.
- Relapsed with documented evidence of relapse more than 12 months after completing
(neo)adjuvant endocrine therapy, without any prior treatment for
advanced/metastatic disease.
- Relapsed with documented evidence of relapse on or within 12 months from
completing (neo)adjuvant endocrine therapy, without any prior treatment for
advanced/metastatic disease.
- Relapsed with documented evidence of relapse more than 12 months after completing
adjuvant endocrine therapy and subsequently progressed after receiving one line
of endocrine therapy (antiestrogen or aromatase inhibitor) for
advanced/metastatic disease.
- Newly diagnosed with advanced/metastatic breast cancer at diagnosis and
progressed after receiving one line of endocrine therapy (antiestrogen or
aromatase inhibitor), with documented evidence of progression.
5. Patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
1.
6. Patients had adequate bone marrow and organ function.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients with symptomatic visceral disease or disease burden that rendered them ineligible
for endocrine therapy, based on the investigator's judgment.
2. Patients who had received prior treatment with chemotherapy (except for
neoadjuvant/adjuvant chemotherapy), fulvestrant, or any CDK4/6 inhibitor.
3. Patients with inflammatory breast cancer at the screening stage. 4. Patients with
central nervous system (CNS) involvement, unless they were at least 4 weeks from completing
prior therapy before initiating the study treatment and had a stable CNS tumor at the time
of screening. They were also required not to be receiving steroids and/or enzyme-inducing
anti-epileptic medications for brain metastases.
5. Patients with clinically significant, uncontrolled heart disease and/or cardiac
repolarization abnormality.
6. Patients who were currently receiving any of the following substances, which could not
be discontinued 7 days prior to initiating treatment:
- Known strong inducers or inhibitors of CYP3A4/5.
- Substances with a known risk of prolonging the QT interval or inducing Torsades de
Pointes.
- Substances with a narrow therapeutic window and predominantly metabolized through
CYP3A4/5.
- Herbal preparations/medications, dietary supplements.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/06/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
11/01/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
726
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - St Leonards
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Herston
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - East Melbourne
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [2]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [3]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Hawaii
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Mississippi
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Jersey
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Mexico
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Utah
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
Tyrol
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Vienna
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Wien
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Aalst
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Charleroi
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Hasselt
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Leuven
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Liege
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Namur
Query!
Country [28]
0
0
Bulgaria
Query!
State/province [28]
0
0
Sofia
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
British Columbia
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
New Brunswick
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Nova Scotia
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Ontario
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Quebec
Query!
Country [34]
0
0
Colombia
Query!
State/province [34]
0
0
Bogota
Query!
Country [35]
0
0
Colombia
Query!
State/province [35]
0
0
Monteria
Query!
Country [36]
0
0
Czechia
Query!
State/province [36]
0
0
Czech Republic
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Brno
Query!
Country [38]
0
0
Czechia
Query!
State/province [38]
0
0
Prague 8
Query!
Country [39]
0
0
Czechia
Query!
State/province [39]
0
0
Praha
Query!
Country [40]
0
0
Denmark
Query!
State/province [40]
0
0
Aalborg
Query!
Country [41]
0
0
Denmark
Query!
State/province [41]
0
0
Aarhus
Query!
Country [42]
0
0
Denmark
Query!
State/province [42]
0
0
Copenhagen
Query!
Country [43]
0
0
Denmark
Query!
State/province [43]
0
0
Herlev
Query!
Country [44]
0
0
Denmark
Query!
State/province [44]
0
0
Odense C
Query!
Country [45]
0
0
Denmark
Query!
State/province [45]
0
0
Vejle
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Cedex
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Hauts De Seine
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Marne
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Besancon Cedex
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Bordeaux Cedex
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Bordeaux
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Brest
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Creteil
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Le Mans Cedex
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Lille Cedex
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Limoges
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Paris 13
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Pierre Benite
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Toulon La Seyne Sur Mer
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Hessen
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Lower Saxony
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Augsburg
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Berlin
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Bielefeld
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Bonn
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Dresden
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Erlangen
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Fuerth
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Hamburg
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Hannover
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Heidelberg
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Koeln
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Luebeck
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Muenchen
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Mühlhausen
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Oldenburg
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Ravensburg
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Saarbruecken
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Troisdorf
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Tuebingen
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Velbert
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Weiden
Query!
Country [83]
0
0
Hungary
Query!
State/province [83]
0
0
Budapest
Query!
Country [84]
0
0
Hungary
Query!
State/province [84]
0
0
Debrecen
Query!
Country [85]
0
0
Hungary
Query!
State/province [85]
0
0
Szolnok
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
AQ
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
BS
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
CT
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
LE
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
MI
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
PI
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Napoli
Query!
Country [93]
0
0
Jordan
Query!
State/province [93]
0
0
Amman
Query!
Country [94]
0
0
Korea, Republic of
Query!
State/province [94]
0
0
Seoul
Query!
Country [95]
0
0
Lebanon
Query!
State/province [95]
0
0
Ashrafieh
Query!
Country [96]
0
0
Lebanon
Query!
State/province [96]
0
0
Beirut
Query!
Country [97]
0
0
Malaysia
Query!
State/province [97]
0
0
Johor
Query!
Country [98]
0
0
Malaysia
Query!
State/province [98]
0
0
Sarawak
Query!
Country [99]
0
0
Mexico
Query!
State/province [99]
0
0
Oaxaca
Query!
Country [100]
0
0
Netherlands
Query!
State/province [100]
0
0
Amsterdam
Query!
Country [101]
0
0
Netherlands
Query!
State/province [101]
0
0
Breda
Query!
Country [102]
0
0
Netherlands
Query!
State/province [102]
0
0
Den Haag
Query!
Country [103]
0
0
Netherlands
Query!
State/province [103]
0
0
Deventer
Query!
Country [104]
0
0
Netherlands
Query!
State/province [104]
0
0
Enschede
Query!
Country [105]
0
0
Netherlands
Query!
State/province [105]
0
0
Groningen
Query!
Country [106]
0
0
Netherlands
Query!
State/province [106]
0
0
Hoofddorp
Query!
Country [107]
0
0
Netherlands
Query!
State/province [107]
0
0
Maastricht
Query!
Country [108]
0
0
Netherlands
Query!
State/province [108]
0
0
Nieuwegein
Query!
Country [109]
0
0
Netherlands
Query!
State/province [109]
0
0
Roermond
Query!
Country [110]
0
0
Netherlands
Query!
State/province [110]
0
0
Sittard-Geleen
Query!
Country [111]
0
0
Netherlands
Query!
State/province [111]
0
0
Tilburg
Query!
Country [112]
0
0
Norway
Query!
State/province [112]
0
0
Oslo
Query!
Country [113]
0
0
Poland
Query!
State/province [113]
0
0
Konin
Query!
Country [114]
0
0
Poland
Query!
State/province [114]
0
0
Warszawa
Query!
Country [115]
0
0
Portugal
Query!
State/province [115]
0
0
Lisboa
Query!
Country [116]
0
0
Portugal
Query!
State/province [116]
0
0
Porto
Query!
Country [117]
0
0
Russian Federation
Query!
State/province [117]
0
0
Arkhangelsk
Query!
Country [118]
0
0
Russian Federation
Query!
State/province [118]
0
0
Tambov
Query!
Country [119]
0
0
Singapore
Query!
State/province [119]
0
0
Singapore
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Andalucia
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Barcelona
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Castilla Y Leon
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Catalunya
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Galicia
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Madrid
Query!
Country [126]
0
0
Sweden
Query!
State/province [126]
0
0
Eskilstuna
Query!
Country [127]
0
0
Sweden
Query!
State/province [127]
0
0
Sundsvall
Query!
Country [128]
0
0
Sweden
Query!
State/province [128]
0
0
Vaxjo
Query!
Country [129]
0
0
Switzerland
Query!
State/province [129]
0
0
Aarau
Query!
Country [130]
0
0
Switzerland
Query!
State/province [130]
0
0
Basel
Query!
Country [131]
0
0
Switzerland
Query!
State/province [131]
0
0
Zuerich
Query!
Country [132]
0
0
Thailand
Query!
State/province [132]
0
0
Bangkok
Query!
Country [133]
0
0
Turkey
Query!
State/province [133]
0
0
Istanbul
Query!
Country [134]
0
0
Turkey
Query!
State/province [134]
0
0
Izmir
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
Devon
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Newcastle Upon Tyne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main aim of this study was to evaluate the efficacy and safety of adding ribociclib to
fulvestrant in men and postmenopausal women with hormone receptor positive (HR+),
HER2-negative advanced breast cancer.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02422615
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02422615
Download to PDF